#United States #Boston #Investor #Neurocrine #Biosciences

Neurocrine Biosciences: Investing in Future Innovations

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a prominent player in the biopharmaceutical industry focused on neuroscience, has announced its participation in two crucial investor conferences scheduled for March 2025. This strategic move aims to highlight the company's ongoing commitment to develop groundbreaking therapies aimed at alleviating the suffering of patients with neurological disorders.

Upcoming Conferences

The first event will take place on March 4, 2025, at the 45th Annual Health Care Conference hosted by TD Cowen in Boston. CEO Kyle Gano will lead discussions alongside CFO Matt Abernethy and Chief Commercial Officer Eric Benevich. Here, they will present insights into the company’s projects and the impact of their therapies on patients’ lives.

Following this, on March 11, 2025, at the Leerink Global Healthcare Conference in Miami, Matt Abernethy, along with Vice-President of Investor Relations Todd Tushla, will share updates on the financial health of the company, discussing future forecasts and strategic initiatives that position Neurocrine as a leader in its field.

Accessing the Webcasts

For those interested in attending these conferences virtually, live webcasts will be available on Neurocrine's official website under the Investors section. After each presentation, a replay will be accessible shortly after the events conclude and will be archived for roughly a month. This provides an excellent opportunity for investors and stakeholders to gain comprehensive insights into the company’s vision and strategies.

About Neurocrine Biosciences

Neurocrine Biosciences has carved a niche in the biopharmaceutical landscape with a focus on addressing unmet medical needs in the domains of neurological, neuroendocrine, and neuropsychiatric disorders. Their commitment is reflected in their diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, Huntington’s disease-related chorea, and endometriosis, among others. Notably, the company has made significant advancements through its recent partnerships to expand its pipeline, demonstrating a relentless pursuit of innovation.

With a history spanning three decades, Neurocrine leverages its extensive insights into the intricate workings of the brain and body to develop solutions for complex health challenges. They firmly stand by their principle that everyone deserves accessible and innovative healthcare solutions. The essence of their commitment is encapsulated in their renowned motto: "You Deserve Brave Science".

Future Outlook

As Neurocrine Biosciences readies to take center stage at these investment platforms, the anticipation grows regarding the revelations about their innovative research and the potential for future growth that these conferences promise. The presence of top executives at such conferences emphasizes the company’s transparency and desire to keep the investment community informed about their latest endeavors.

For more in-depth coverage and updates on Neurocrine Biosciences’ latest announcements, interested parties are encouraged to follow them on social media platforms such as LinkedIn, X (formerly Twitter), and Facebook.

Both conferences present a significant opportunity for investors to engage directly with the company’s leadership, reflecting Neurocrine's ongoing mission to provide impactful and transformative healthcare solutions for those in dire need of innovative treatments. As they move forward, investors and patients alike will be keenly watching how Neurocrine shapes the future of neurological healthcare.